PSOX化疗方案在胃癌的研究进展
Research Progress of PSOX Chemotherapy Regimen in Gastric Cancer
DOI: 10.12677/ACM.2023.1351070, PDF,   
作者: 孙爽爽：青海大学研究生院，青海 西宁；才保加*：青海大学附属肿瘤医院肿瘤外科，青海 西宁
关键词: 胃癌；PSOX化疗方案；综述文献；Gastric Cancer； PSOX Chemotherapy Scheme； Review Literature
摘要: 胃癌是全球最常见的消化道肿瘤之一，其发病率和病死率逐年增高。手术、化疗以及放疗的联合治疗手段在胃癌中也越来越常见，尽管在胃癌的临床治疗上取得了一定的效果，但在胃癌患者生存预后、毒副反应以及生活质量上仍不理想。因此为了克服种种化疗药物带来的副作用，近年来研究出一种纳米制剂——白蛋白紫杉醇(nab-paclitaxel)。白蛋白紫杉醇由白蛋白与紫杉醇组成，主要通过抑制微管的动力学，抑制有丝分裂从而肿瘤细胞死亡，具有抗肿瘤效果好、抑制腹膜转移、毒副作用小和操作方便等优点，因此nab-紫杉醇在各种恶性肿瘤中的研究和应用已逐步向联合的方向发展。本文就PSOX化疗方案在胃癌治疗中的研究进展作一综述。
Abstract: Gastric cancer is one of the most common gastrointestinal tumors in the world, and its incidence rate and mortality are increasing year by year. The combined treatment of surgery, chemotherapy and radiotherapy is also more and more common in gastric cancer. Although it has achieved certain results in the clinical treatment of gastric cancer, it is still not ideal in the survival prognosis, toxici-ty and quality of life of gastric cancer patients. Therefore, in order to overcome the side effects of various chemotherapy drugs, a nano preparation-albumin paclitaxel (nab-paclitaxel) has been de-veloped in recent years. Albumin paclitaxel is composed of albumin and paclitaxel. It mainly inhib-its mitosis and tumor cell death by inhibiting the dynamics of microtubules. It has the advantages of good anti-tumor effect, inhibition of peritoneal metastasis, small toxic side effects and easy opera-tion. Therefore, the research and application of nab-paclitaxel in various malignant tumors have gradually developed in the direction of combination. This article reviews the research progress of PSOX chemotherapy in the treatment of gastric cancer.
文章引用：孙爽爽, 才保加. PSOX化疗方案在胃癌的研究进展[J]. 临床医学进展, 2023, 13(5): 7659-7664. https://doi.org/10.12677/ACM.2023.1351070

参考文献

[1] Gao, K. and Wu, J. (2019) National Trend of Gastric Cancer Mortality in China (2003-2015): A Population-Based Study. Cancer Communications, 39, 1-5. [Google Scholar] [CrossRef] [PubMed]
[2] 叶磊, 陈文. 紫杉醇腹腔灌注化疗治疗晚期胃癌合并恶性腹水的临床疗效观察[J]. 重庆医科大学学报, 2020, 45(9): 1279-1284.
[3] Cunning-ham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine, 355, 11-20. [Google Scholar] [CrossRef] 
[4] Ychou, M., Boige, V., Pignon, J.P., et al. (2011) Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 29, 1715-1721. [Google Scholar] [CrossRef] 
[5] D’Angelica, M., Gonen, M., Brennan, M.F., Turnbull, A.D., Bains, M. and Karpeh, M.S. (2004) Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma. Annals of Surgery, 240, 808-816. [Google Scholar] [CrossRef] [PubMed]
[6] 加雄, 郭亚焕, 曾述洪. 白蛋白结合型紫杉醇联合奥沙利铂、低剂量替吉奥治疗老年晚期贲门癌的效果及对肿瘤标志物、Hsp90α、CXCL4水平的影响[J]. 临床医学研究与实践, 2022, 7(27): 49-53.
[7] 钟文. PSOX方案在进展期胃癌新辅助化疗中有效性和临床安全性研究[D]: [硕士学位论文]. 西宁: 青海大学, 2021.
[8] Wang, H.-Y., Yao, Z.-H., Tang, H., Zhao, Y., Zhang, X.-S., Yao, S.-N., et al. (2016) Weekly Nanoparticle Albumin-Bound Paclitaxel in Combination with Cisplatin Versus Weekly Sol-vent-Based Paclitaxel Plus Cisplatin as First-Line Therapy in Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma. OncoTargets and Therapy, 9, 5663-5669. [Google Scholar] [CrossRef] 
[9] Shitara, K., Ta-kashima, A., Fujitani, K., Koeda, K., Hara, H., Nakayama, N., et al. (2017) Nab-Paclitaxel versus Solvent-Based Paclitaxel in Patients with Previously Treated Advanced Gastric Cancer (ABSOLUTE): An Open-Label, Randomised, Non-Inferiority, Phase 3 Trial. The Lancet Gastroenterology and Hepatology, 2, 277-287. [Google Scholar] [CrossRef] 
[10] Schiff, P.B. and Horwitz, S.B. (1980) Taxol Stabilizes Mi-crotubules in Mouse Fibroblast Cells. Proceedings of the National Academy of Sciences of the United States of America, 77, 1561-1565. [Google Scholar] [CrossRef] [PubMed]
[11] Verweij, J., Clavel, M. and Chevalier, B. (1994) Paclitaxel (Taxol) and Docetaxel (Taxotere): Not Simply Two of a Kind. Annals of Oncology, 5, 495-505. [Google Scholar] [CrossRef] [PubMed]
[12] Tiruppathi, C., Song, W., Bergenfeldt, M., Sass, P. and Malik, A.B. (1997) Gp60 Activation Mediates Albumin Transcytosis in Endothelial Cells by Tyrosine Ki-nase-Dependent Pathway. Journal of Biological Chemistry, 272, 25968-25975. [Google Scholar] [CrossRef] [PubMed]
[13] Weiss, R.B., Donehower, R.C., Wiernik, P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., Baker Jr., J.R., Van Echo, D.A., Von Hoff, D.D. and Leyland-Jones, B. (1990) Hypersensitivity Re-actions from Taxol. Journal of Clinical Oncology, 8, 1263-1268. [Google Scholar] [CrossRef] 
[14] Irizarry, L.D., Luu, T.H., McKoy, J.M., Samaras, A.T., Fisher, M.J., Carias, E.E., Raisch, D.W., Calhoun, E.A. and Bennett, C.L. (2009) Cremophor El-Containing Paclitaxel-Induced Anaphylaxis: A Call to Action. Community Oncology, 6, 132-134. [Google Scholar] [CrossRef] 
[15] Schnitzer, J.E. (1992) Gp60 Is an Albumin-Binding Glyco-protein Expressed by Continuous Endothelium Involved in Albumin Transcytosis. American Journal of Physiolo-gy-Heart and Circulatory Physiology, 262, H246-H254. [Google Scholar] [CrossRef] 
[16] 周际昌. 实用肿瘤内科学[M]. 第2版. 北京: 人民卫生出版社, 2003: 395-397.
[17] Rixe, O., Ortuzar, W., Alvarez, M., et al. (1996) Oxaliplatin, Tetraplatin, Cisplatin, and Carboplatin: Spectrum of Activity in Drug-Resistant Cell Lines and in the Cell Lines of the National Cancer Institute’s Anticancer Drug Screen Panel. Biochemical Pharmacology, 52, 1855-1865. [Google Scholar] [CrossRef] 
[18] 张建国, 郑国宝. 多西他赛联合替吉奥治疗晚期胃癌的疗效及作用机制分析[J]. 实用中西医结合临床, 2022, 22(15): 16-19.
[19] 缪敏, 丁倩, 蔡培培, 王磊. 周剂量白蛋白结合型紫杉醇联合SOX方案一线治疗晚期胃癌的临床观察[J]. 吉林医学, 2022, 43(11): 2982-2984.
[20] 刘子田, 王晓阳, 祝新, 等. 白蛋白结合型紫杉醇联合奥沙利铂和替吉奥在局部不可切除的进展期胃癌转化治疗中的应用[J]. 中国现代普通外科进展, 2021, 24(5): 374-377, 383.

为你推荐